Journal list menu

Volume 393, Issue 1 p. 86-88
Research letter
Free Access

Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria

Yuri V. Evtodienko

Yuri V. Evtodienko

Institute of Theoretical and Experimental Biophysics, Pushchino, Russian Federation

Groupe d'Etude des Systèmes Biologiques Integrés, D(BM) 2 , Université Bordeaux II, 33076 Bordeaux Cedex, France

Search for more papers by this author
Vera V. Teplova

Vera V. Teplova

Institute of Theoretical and Experimental Biophysics, Pushchino, Russian Federation

Search for more papers by this author
Serguei S. Sidash

Serguei S. Sidash

Institute of Theoretical and Experimental Biophysics, Pushchino, Russian Federation

Groupe d'Etude des Systèmes Biologiques Integrés, D(BM) 2 , Université Bordeaux II, 33076 Bordeaux Cedex, France

Search for more papers by this author
François Ichas

François Ichas

Groupe d'Etude des Systèmes Biologiques Integrés, D(BM) 2 , Université Bordeaux II, 33076 Bordeaux Cedex, France

Search for more papers by this author
Jean-Pierre Mazat

Jean-Pierre Mazat

Groupe d'Etude des Systèmes Biologiques Integrés, D(BM) 2 , Université Bordeaux II, 33076 Bordeaux Cedex, France

Search for more papers by this author
First published: September 09, 1996
Citations: 47
Corresponding author. Fax: (33) 56 99 03 80.

Abstract

We report the effects of anticancer drugs, inhibitors of microtubule organisation, on the mitochondrial permeability transition pore (PTP) in Ehrlich ascites tumour cells. Taxol (5–20 μM) and colchicine (100–500 μM) prevented closing of the cyclosporin A-sensitive PTP. No taxol or colchicine effects on oxidative phosphorylation were observed in the range of concentrations used. We suggest that either membrane-bound tubulin per se can be part of PTP and/or the attachment of mitochondria to the microtubular network is essential for PTP regulation. The taxol inhibition of PTP closure, mediated through interaction with the cytoskeleton, sheds new light on the cytotoxic properties of this anticancer drug.